New Serious Adverse Effects With Alemtuzumab in MS New Serious Adverse Effects With Alemtuzumab in MS
Several new and potentially life-threatening adverse events associated with the use of this novel agent for multiple sclerosis have been reported.Medscape Medical News
By collecting data on MS patients’ activities and abilities, parent company Roche Group hopes to create new drugs and diagnostics to combat this deadly disease Biotechnology company Genentech, a subsidiary of multinational pharmaceutical/diagnostics company Roche Holdings AG, has developed a smartphone application (app) that enables patients with Multiple Sclerosis (MS) to monitor and track their […]
Katja Vohl, Alexander Duscha, Barbara Gisevius, Johannes Kaisler, Ralf Gold, Aiden Haghikia
Tobias D. Faizy, Gabriel Broocks, Christian Thaler, Geraldine Rauch, Pimrapat Gebert, Klarissa H. St ürner, Fabian Flottmann, Hannes Leischner, Helge C. Kniep, Jan-Patrick Stellmann, Christoph Heesen, Jens Fiehler, Susanne Gellißen, Uta Hanning
No abstract available
No abstract available
(Kessler Foundation) Dr. Dobryakova conducts clinical research in populations with cognitive dysfunction caused by traumatic brain injury and multiple sclerosis. She incorporates functional neuroimaging in her research, which focuses on the activity of the fronto-striatal network in fatigue and outcome processing in these populations. Her findings indicate that noninvasive, nonpharmacologic interventions may be useful for addressing deficits in learning processes, and in ameliorating the impact of debilitating cognitive fatigue.
Manca, A, Dvir, Z, and Deriu, F. Meta-analytic and scoping study on strength training in people with multiple sclerosis. J Strength Cond Res 33(3): 874–889, 2019—Aim of the study was to determine a pooled estimate of effect on muscle strength and functional capacity induced by strength training in people with multiple sclerosis (PwMS). Five databases and 2 public registries were searched from inception to May 2017. Indexing terms used were: “multiple sclerosis,” “resistance training,” and “strength training.” After title/abstract screening, 2 independent reviewers evaluated t...
In conclusion, there is much to explore with post-mortem MRI and histology studies, which can eventually be of high relevance for clinical pra ctice.
A new patient-reported outcome (PRO) instrument to measure fatigue symptoms and impacts in relapsing multiple sclerosis (RMS) was developed in a qualitative stage, followed by psychometric validation and migration from paper to an electronic format.
Condition: Multiple Sclerosis Intervention: Drug: Fampridine Sponsors: University of Southern Denmark; Odense University Hospital; Sygehus Lillebaelt; University of Miami; Region of Southern Denmark; The Augustinus Foundation, Denmark.; The Lounkaer Foundation; Fonden for scleroseramte paa Fyn; The Danish Multiple Scle rosis Society; The Lily Benthine Lunds Foundation Recruiting